

SIMRIS ALG: Video Interview with SIMRIS CEO Julian Read and CYANO BIOTECH Co-Founder Dan Enke

In the interview CEO Julian Read discusses

- Why Simris has acquired Berlin-based cyanobacteria firm CYANO BIOTECH
- His plan for SIMRIS' entry into the biopharma space
- The outlook for SIMRIS' revenue distribution in 2023 and long term
- His top priorities as CEO for the next 12 months

Also hear CYANO BIOTECH Co-Founder Dan Enke discuss why cyanobacteria is such a good fit as payload in the emerging ADC cancer treatments.

See the video interview here https://youtu.be/pl_fx21izFg

Also read our research report on SIMRIS here https://www.emergers.se/simris_m/

Contact

Johan Widmark

johan@emergers.se

About Emergers

This is a press release from Emergers.

DISCLAIMER

Information provided here or on Emergers' website [emergers.se](https://www.emergers.se) is not intended to be financial advice. Emergers receives compensation for writing about the company in question. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers' own. Articles of analysis shall not be construed as a recommendation or solicitation to invest in the companies described. Emergers cannot guarantee that the conclusions presented in the analysis will be met. Emergers cannot be held liable for either direct or indirect damages caused by decisions made on the basis of information in this analysis. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.

For more information and complete terms, please see [emergers.se](https://www.emergers.se).



Attachments

[SIMRIS ALG: Video Interview with SIMRIS CEO Julian Read and CYANO BIOTECH Co-Founder Dan Enke](#)